Skip to content

A randomized controlled multicenter trial of surgical biological patch for the prevention of cesarean scar defect

A randomized controlled multicenter trial of surgical biological patch for the prevention of cesarean scar defect

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200063912
Enrollment
Unknown
Registered
2022-09-20
Start date
2022-09-20
Completion date
Unknown
Last updated
2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cesarean scar defect

Interventions

Experimental group:Surgical biological patch implanted and double suture
Control group:Conventional double suture

Sponsors

Women's Hospital School of Medicine Zhejiang University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. Puerpera aged 18 to 40 years. 2. The indications of operation for the first cesarean section was assessed to determine by the investigator based on the medical history, physical examination, laboratory tests, electrocardiogram, B-ultrasound, and maternal willingness. 3. Effective contraceptive measures should be taken 6 months after operation. 4. Able to understand the purpose of the trial, willing to cooperate with surgical treatment and follow-up, voluntarily participate in the trial and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Cesarean section for three or more multiple births. 2. Preoperative premature rupture of membranes, uterine infection, genital tract inflammation and other infectious diseases. 3. Severe obstetric complications and complications (such as pulmonary hypertension, placenta accreta, preeclampsia, etc.). 4. Previous myomectomy penetrating the uterine cavity. 5. Severe autoimmune diseases (such as type 1 diabetes mellitus, rheumatoid arthritis, systemic lupus erythematosus, etc.). 6. Allergic history to porcine fibrinogen and polylactide caprolactone (PL-Cl). 7. MRI examination could not be performed due to claustrophobia or other reasons. 8. Participants in any interventional clinical trial within the past 60 days. 9. Other factors deemed unsuitable for trial participation by the investigator.

Design outcomes

Primary

MeasureTime frame
Effective rate of preventing cesarean scar defect after 24 weeks after operation;

Secondary

MeasureTime frame
Effective rate of preventing cesarean scar defect after 12 weeks after operation;Incidence of symptomatic cesarean scar defect at 12 and 24 weeks after operation;Incidence of severe cesarean scar defect at 12 and 24 weeks after operation;Incidence of postoperative cesarean scar infection;

Countries

China

Contacts

Public ContactWang Zhengping
wangzp@zju.edu.cn+86 13705715269

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026